Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

420 results about "Mycotic infection" patented technology

DISTINCTIVE PROPERTIES: Mycotic infections are classified by the tissue levels that are colonized. Superficial infections are generally limited to the outer layers of the skin and hair. In addition, mycotic infections may be systemic, generally originating in the lungs.

Anti-fungal formulation of triterpene and essential oil

The present invention provides for pharmaceutical compositions that includes a triterpene (e.g., betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides for a cosmetic formulation that includes a triterpene (e.g., betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides a method of treating a fungal infection that includes administering (e.g., topically applying) an effective amount of the pharmaceutical composition to the tissue afflicted with the fungal infection, or the tissue at risk of being afflicted with the fungal infection.
Owner:NATURNORTH TECH +1

Methods and Kits for Preventing the Spread of Sexually Transmitted Microorganisms

This application is directed to methods and kits for preventing the spread of sexually transmitted microorganisms among individuals. The present method is for the application of a medicament comprising an irrigant to an area of the body having, or which may have, a lesion resulting from, for example, a viral, bacteria or fungal infection, thereby damaging the microorganism within the lesion and preventing the organism from infecting human cells.
Owner:BLOCK ROBERT M

Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors

In its many embodiments, the present invention provides -substituted pyridazinone compounds as glucan synthase inhibitors, methods of preparing such compounds, pharmaceutical including one or more of such compounds, methods of preparing pharmaceutical formulations including one or more such compounds or one or more such compounds along with other antifungal agents, and methods of treatment, prevention, inhibition, or amelioration of one or more fungal infections associated with glucan synthase using such compounds or pharmaceutical compositions.
Owner:ALBANY MOLECULAR RESEARCH INC +1

Novel topical formulations of flucytosine and uses thereof

InactiveUS20090068287A1Promote resultsLimited systemic exposureBiocideOrganic active ingredientsSide effectWhole body
The invention relates to topical formulations and methods of use of flucytosine which demonstrate a clear advantage over currently available therapeutic regimens for the treatment and maintenance of fungal infections, particularly vulvovaginal candidiasis. The invention provides compositions which solve the long-standing need for antimicrobial agents which treat effectively resistant strains of Candida spp., especially C. albicans, C. glabrata, and C. tropicalis, and which pose limited risk of side effects, adverse reactions, or the development of resistant pathogens. The invention provides novel topical formulations of flucytosine designed to allow the active drug to act at the local application area, but which inhibit or moderate transdermal or transmucosal absorption of the drug, thus limiting systemic exposure.
Owner:CAMARGO PHARMA SERVICES

Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use

The invention describes compositions and kits comprising at least one nitric oxide enhancing group antimicrobial compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The antimicrobial compounds of the invention are preferably tobramycin, aztreonam, ciprofloxacin and doripenam. The nitric oxide enhancing antimicrobial compounds are substituted with at least one heterocyclic nitric oxide donor group and / or at least one nitroxide group. The nitric oxide enhancing groups are nitroxides and / or heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and / or oxatriazole-5-imines. In one embodiment the methods of the invention are for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating Bacillus anthracis infections.
Owner:NICOX SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products